We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current CSCI market cap is 20.01M. The company's latest EPS is USD -3.4086 and P/E is -1.21.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 532k | 3.87M | 5.26M | 5.64M | 4.5M |
| Operating Income | -10.04M | -5.96M | -5.33M | -20.99M | -18.01M |
| Net Income | -6.04M | -5.12M | -8.37M | -22.73M | -16.55M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 19.98M | 37.28M | 80.1M | 56.03M | 37.02M |
| Total Liabilities | 22.44M | 24.07M | 27.12M | 20.25M | 18.82M |
| Total Equity | -2.46M | 13.21M | 52.99M | 35.78M | 18.2M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -10.73M | -4.13M | -8.58M | -13.68M | -17.12M |
| Investing | 50k | 56k | -658k | -12k | 528k |
| Financing | 3.89M | 20.47M | 51.04M | -118k | -151k |
| Market Cap | 20.01M |
| Price to Earnings Ratio | -1.21 |
| Price to Sales Ratio | 4.45 |
| Price to Cash Ratio | 0.59 |
| Price to Book Ratio | 1.1 |
| Dividend Yield | - |
| Shares Outstanding | 4.86M |
| Average Volume (1 week) | 4.98k |
| Average Volume (1 Month) | 2.52k |
| 52 Week Change | -50.95% |
| 52 Week High | 9.00 |
| 52 Week Low | 3.78 |
| Spread (Intraday) | 0.18 (4.26%) |
| Company Name | COSCIENS Biopharma Inc |
| Address |
aeterna zentaris inc toronto, ontario M5K 1E7 |
| Website | https://www.zentaris.com/ |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
